Holen Sie sich die Stockscreener-App
0.998
0.43%
0.0108
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TPST?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$0.9872
Offen:
$0.985
24-Stunden-Volumen:
30,337
Relative Volume:
0.16
Marktkapitalisierung:
$16.29M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-43.10M
KGV:
-0.1607
EPS:
-6.2098
Netto-Cashflow:
$-26.38M
1W Leistung:
-9.87%
1M Leistung:
+8.15%
6M Leistung:
-58.52%
1J Leistung:
-81.97%
1-Tages-Spanne:
$0.96
$0.99
1-Wochen-Bereich:
$0.96
$1.10
52-Wochen-Spanne:
$0.8401
$6.115
Tempest Therapeutics Inc Stock (TPST) Company Profile
Firmenname
Tempest Therapeutics Inc
Sektor
Branche
Telefon
415-798-8589
Adresse
2000 SIERRA POINT PARKWAY, BRISBANE
Compare TPST vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TPST
Tempest Therapeutics Inc
|
0.9849 | 16.33M | 0 | -43.10M | -26.38M | -6.2098 |
VRTX
Vertex Pharmaceuticals Inc
|
522.83 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
800.17 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.20 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.32 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.18 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-22 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-04-10 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-04-10 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2024-03-14 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-02-08 | Eingeleitet | Jefferies | Buy |
Tempest Therapeutics Inc Aktie (TPST) Neueste Nachrichten
Tempest Therapeutics secures $50M equity purchase agreement with Lincoln Park - scanx.trade
Tempest Therapeutics CEO to present at H.C. Wainwright Global Investment Conference - Bitget
A biotech CEO will speak Sept. 15; Tempest will archive the webcast - Stock Titan
Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire
Tempest Therapeutics, Inc. SEC Filing (Sep 1, 2026) - Stock Titan
Tempest Therapeutics (TPST) Slips 1.85% to $1.06 as Shares Test Support at $1.01Cup and Handle - siam.in
Tempest TherapeuticsJustin Trojanowski To Resign As Principal Financial Officer And Principal Accounting Officer Effective Sept 1SEC Filing - TradingView
Tempest (TPST) Results at a Glance: Reported EPS Misses Expectations at the Close; Trading Move: The Stock Records a 1.96% Increase in Latest TradingProfit Guidance Range - vinanet.vn
Tempest Therapeutics files prospectus for sale of 8.9 million shares - scanx.trade
Tempest Therapeutics (NASDAQ: TPST) lines up $50M stock facility that may heavily dilute holders - Stock Titan
Tempest (TPST) Results Versus Estimates: The EPS Result Is Below Expectation in Latest Trading; Latest Reaction: The Stock Loses 4.58% in the Available RecordProfit Recovery Report - vinanet.vn
Tempest partners Senlang to advance TPST-4003 in China trial - scanx.trade
Form 8K Tempest Therapeutics Inc For: 18 August By Investing.com - Investing.com South Africa
Tempest Therapeutics adjourns special meeting, sets new date for stockholder vote - Investing.com
Tempest Therapeutics Adjourns Special Stockholder Meeting Again - TipRanks
TPST Q1 2026 Earnings: Wider-Than-Expected Losses as Shares Gain 11.33%Balance Sheet Strength - vinanet.vn
Tempest Therapeutics (TPST) Stock Forum and Discussion - Moomoo
TPST Q1 2026 Earnings: EPS Deeply Misses Estimates as No Revenue ReportedPositive Surprise Momentum - Vinanet
TPST Q1 2026 Earnings: Clinical-Stage Biotech Reports Deep EPS Miss as Shares Slide 13.25%EPS Surprise History - vinanet.vn
Tempest Therapeutics Cash Drops to $0.8M Amid Recent Asset Acquisition - Minichart
Tempest Therapeutics Secures Up to $50 Million Equity Facility From Lincoln Park - Minichart
Tempest Therapeutics Cash Drops to $0.8 Million, Raising Going-Concern Risk - Minichart
Form 8K Tempest Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
Tempest Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Tempest Therapeutics Secures Flexible $50 Million Equity Facility - TipRanks
Tempest Therapeutics Q2 loss narrows to $5.2m; advances CAR-T pipeline - scanx.trade
Tempest Therapeutics (TPST) expands CAR-T pipeline amid $32.9M loss and cash strain - Stock Titan
Tempest Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Tempest Therapeutics Announces Senlang Collaboration to Advance TPST-4003 In Vivo CAR-T Pipeline and Appoints Two New Directors - Quiver Quantitative
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
Tempest Therapeutics Inc (TPST) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits
Tempest Therapeutics (TPST) Surges 13% as Biotech Momentum Builds Above Key SupportAnalyst Downgrade Signals - vinanet.vn
Tempest Therapeutics Inc expected to post a loss of 30 cents a shareEarnings Preview - TradingView
Tempest Therapeutics (TPST) Gains 3% as Biotech Stock Holds Ground Above $0.86 SupportAnchored VWAP - dars.gov.et
Tempest Therapeutics (TPST) Slides to $0.86, Testing Support Near $0.82Range Breakout - vinanet.vn
Tempest Therapeutics (TPST) Shows Modest Uptick, Holding Above Key SupportPrice Target - vinanet.vn
Tempest Therapeutics Inc (TPST) Institutional Confidence - TradingKey
Tempest Therapeutics Adjourns Vote on Governance Changes - TipRanks
Tempest Therapeutics Inc (TPST) Cash Flow - TradingKey
TPST|Tempest Therapeutics Inc|Price:0.942|Chg%:+0.016 - TradingKey
Tempest Therapeutics Inc (TPST) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
Tempest Therapeutics Inc (TPST) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tempest Therapeutics, Inc. Revenue Breakdown – NASDAQ:TPST - TradingView
Tempest Therapeutics Inc (TPST) Valuation: PE, PB & Fair Value Analysis - TradingKey
TPST Q1 2026 Earnings: Wide EPS Miss Highlights Cash Burn ChallengesEarnings Growth Forecast - vinanet.vn
Tempest Therapeutics (TPST) Slightly Declines as Stock Nears Support LevelBuy Signal Reports - dars.gov.et
Tempest Therapeutics inks China in vivo CAR-T deal - TipRanks
Tempest Therapeutics, Inc. and Heibei Senlang Biotechnology Co., Ltd. Enter into Product Development and Investigator-Initiated Trial Collaboration Agreement - marketscreener.com
Tempest Therapeutics (TPST) Pulls Back to $0.97, Testing Key SupportSign of Weakness - dars.gov.et
Tempest Therapeutics Announces Strategic Partnership with Senlang to Advance TPST-4003 into First-in-Human Study in Autoimmune Diseases - Quiver Quantitative
Finanzdaten der Tempest Therapeutics Inc-Aktie (TPST)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):